Inhibrx Biosciences, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company with two principal clinical programs, ozekibart (INBRX-109) and INBRX-106. Form 8-K reports furnish financial results, Regulation FD presentations, and clinical updates covering oncology studies in chondrosarcoma, colorectal cancer, Ewing sarcoma, head and neck squamous cell carcinoma, and non-small cell lung cancer.
The company’s proxy materials describe annual meeting matters, board elections, executive compensation and equity incentive governance. Its filings also identify Inhibrx Biosciences as an emerging growth company and provide formal disclosures on operating results, pipeline development, capital resources, risk factors, and the completed 2024 separation from Inhibrx, Inc.
Inhibrx Biosciences, Inc. (INBX) reported positive randomized Phase 2 data from its HexAgon study of INBRX-106 plus pembrolizumab in first-line PD-L1–positive metastatic or unresectable recurrent HNSCC. Among 63 evaluable patients at an August 19, 2026 cutoff, the combination achieved a confirmed objective response rate of 48.3% versus 26.5% for pembrolizumab alone, including complete responses in 13.8% of combination patients and none on monotherapy.
Median progression-free survival was 9.6 months for the combination versus 4.9 months for pembrolizumab, with six‑month PFS rates of 72.4% and 42.8%, respectively. In HPV+ patients, cORR was 80.0% vs 33.3%, with 30.0% complete responses and 90.0% six‑month PFS for the combination versus 0% complete responses and 33.0% six‑month PFS for pembrolizumab. The combination’s safety profile was generally manageable, with mostly low‑grade rash, fatigue, and diarrhea.
Based on these results, Inhibrx plans to expand the randomized Phase 2 portion of HexAgon by approximately 50 additional HPV+ OPSCC patients (CPS ≥ 1) to support a potential accelerated regulatory pathway, then initiate a Phase 3 confirmatory trial after alignment with the FDA. INBRX-106 is also being studied in a Phase 1/2 perioperative NSCLC trial with an initial data readout targeted by mid‑2027 and is being positioned for broader use in highly immunogenic tumors and in combination with therapeutic cancer vaccines.
Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. report beneficial ownership of 1,489,443 shares of Inhibrx Biosciences, Inc. common stock, representing 9.99% of the class. This percentage is based on 14,717,660 shares outstanding as of August 7, 2026, plus shares issuable under certain warrants.
The Master Fund directly holds 1,297,763 common shares and 732,157 pre-funded warrants, each immediately exercisable at $0.0001 per share. Because of a 9.99% Beneficial Ownership Limitation, the reporting group currently may exercise warrants for only 191,680 shares, and assumes the remaining warrants are not exercisable for ownership-calculation purposes. Perceptive Advisors, as investment manager, and Mr. Edelman, as managing member, may be deemed to share voting and dispositive power over the same 1,489,443 shares.
Inhibrx Biosciences, Inc. received a large shareholder disclosure from Schonfeld Strategic Advisors LLC, a Delaware limited liability company and investment adviser to several private funds and separately managed accounts. Schonfeld reports beneficial ownership of 781,678 shares of Inhibrx Biosciences common stock, representing 5.33% of the outstanding class. This percentage is based on 14,671,186 shares outstanding as of May 8, 2026, as reported in Inhibrx Biosciences’ quarterly report for the period ended March 31, 2026. Schonfeld has sole voting and dispositive power over these 781,678 shares, while its clients, on whose behalf the securities are held, have the right to receive dividends and sale proceeds. Schonfeld states that the filing should not be construed as an admission that it is the beneficial owner of these securities for any legal purpose.
Inhibrx Biosciences, Inc. is reported to have a significant shareholder group led by Viking Global entities and individuals O. Andreas Halvorsen and Rose S. Shabet. These reporting persons collectively beneficially own 1,383,621 shares of Common Stock, including shares underlying warrants to purchase 259,692 shares at an exercise price of $0.0001 per share. Based on 14,671,186 shares outstanding as of May 8, 2026 plus the warrant shares, their beneficial ownership represents up to 9.3% of the class. Voting and dispositive powers are held on a shared basis through a complex structure of Delaware and Cayman Islands investment entities managed by Viking Global Investors LP and related general partners.
Inhibrx Biosciences, Inc. reported second quarter 2026 results with a net loss of $36.7 million, or $2.34 per share, compared to a net loss of $28.7 million a year earlier. The company reported no revenue in the quarter versus $1.3 million in Q2 2025.
Research and development expenses were $23.9 million and general and administrative expenses were $8.3 million, both higher than the prior-year period, while total other expense rose to $4.5 million mainly from increased interest on debt. As of June 30, 2026, cash and cash equivalents were $133.3 million; including proceeds from a July loan amendment, cash reached $219.5 million as of August 6, 2026. A second amendment to the Oxford Finance loan provides up to $325.0 million in additional gross proceeds, of which $100.0 million was funded. The FDA accepted the biologics license application for ozekibart in conventional chondrosarcoma with a PDUFA goal date of April 14, 2027, and the company plans further clinical and regulatory milestones for ozekibart and INBRX-106.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing the DR5 agonist ozekibart (INBRX-109) and the OX40 agonist INBRX-106. Cash and cash equivalents were $133.3 million as of June 30 2026, with an accumulated deficit of $316.3 million and a stockholders’ equity deficit of $53.0 million.
For the six months ended June 30 2026, the company generated no revenue versus $1.3 million a year earlier, incurred research and development expenses of $49.1 million (down 17%), general and administrative expenses of $14.0 million (up 12%), and reported a net loss of $70.1 million. Long‑term debt under the Oxford facility totaled $176.3 million, with an effective interest rate of 17.5%, and a subsequent amendment in July 2026 added up to $325.0 million of additional borrowing capacity, including $100.0 million already drawn.
Clinically, ozekibart showed a statistically significant progression‑free survival benefit in a registrational chondrosarcoma trial, and a biologics license application was accepted by the FDA in June 2026. Interim data in colorectal cancer and Ewing sarcoma, and positive Phase 2 HexAgon data for INBRX‑106 in head and neck cancer, support further late‑stage development.
Inhibrx Biosciences, Inc. has a significant institutional shareholder position reported by Bank of America Corporation and certain of its wholly owned subsidiaries. Bank of America reports beneficial ownership of 857,318 shares of common stock, representing 5.9% of the class, based on 14,607,286 shares outstanding as referenced from an issuer Form 8-K exhibit.
The position is held with no sole voting or dispositive power, but with shared voting power over 857,306 shares and shared dispositive power over 857,318 shares. The filing attributes the holdings to multiple affiliated entities, including BofA Securities, Inc., Bank of America, N.A., Merrill Lynch International, Merrill Lynch Pierce Fenner & Smith, Inc., and U.S. Trust Co of Delaware, with Bank of America Corporation filing on their behalf.
Inhibrx Biosciences, Inc. entered into a Second Amendment to its Loan and Security Agreement with Oxford Finance, expanding its Credit Facility to an aggregate principal amount of $500.0 million.
The amendment adds an additional tranche of up to $325.0 million, including a $100.0 million Term C Loan funded at signing and up to $225.0 million of Term D Loans that may be drawn in increments of $50.0 million or more at the Lenders’ sole discretion upon the company’s request. Prior to the amendment, Inhibrx had drawn $175.0 million under the facility.
In connection with the Term C funding, Inhibrx issued the Lenders warrants to purchase 21,457 common shares at an exercise price of $93.21 per share, stated as equal to 2.0% of the Term C Loan value, exercisable immediately for 10 years, with anti-dilution adjustments. Additional warrants sized at 2.0% of any Term D funding will be issued on similar pricing mechanics. Inhibrx also pledged all of its equity in Poplar Therapeutics, Inc. as collateral. The warrants were issued in transactions exempt from registration under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D.
Inhibrx Biosciences reported that the U.S. FDA has accepted for filing its Biologics License Application for ozekibart (INBRX-109) to treat patients with unresectable or metastatic conventional chondrosarcoma and has set a PDUFA goal date of April 14, 2027.
The BLA is backed by the registrational ChonDRAgon study, where ozekibart cut the risk of disease progression or death by 52% versus placebo (hazard ratio 0.479) and more than doubled median progression-free survival to 5.52 months vs 2.66 months. Disease control rate and pain and function measures also favored ozekibart.
If approved, ozekibart would be Inhibrx’s first commercial product and the first FDA‑approved systemic therapy for this cancer. The drug showed a generally manageable safety profile, with hepatotoxicity mitigated through patient selection and close monitoring.
Inhibrx Biosciences director Kristiina Vuori, MD, received a grant of stock options for 15,000 shares of common stock. The options have an exercise price of $95.22 per share, become fully exercisable on June 3, 2027, subject to her continued service, and expire on June 3, 2036.